Daily Stock Setups

ArQule Presents Data at AACR-NCI-EORTC Conference

Posted on: Tue, 17 Nov 2009 22:51:00 EST

Symbols: ARQL

Are you looking to increase your ETF knowledge?

Nov 18, 2009 (Close-Up Media via COMTEX) --
ARQL | Quote | Chart | News | PowerRating -- ArQule, Inc. said that it has presented data at the AACR-NCI-EORTC meeting in Boston demonstrating the capabilities of the Company's proprietary drug discovery platform to generate a class of small molecules with significant therapeutic potential.

In a release, the Company noted that these data reflect the results of the application of the ArQule Kinase Inhibitor Platform (AKIP) to discover and optimize a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR) that are not ATP-competitive and show potent anti-tumor activity in FGFR-driven cancer models.

ArQule said that several compounds from this program showed marked pharmacodynamic suppression of FGFR2 and corresponding growth inhibition in human gastric carcinoma cell lines. Growth of gastric carcinoma tumor xenografts in athymic mice was significantly inhibited after daily administration of a prototype compound for nine days, with a number of animals being cured of their tumors with this regimen.

"The information presented demonstrates the speed and efficiency of ArQule's proprietary, structure-based drug discovery platform to identify chemically novel kinase inhibitors that are not classically ATP-competitive," said Dr. Thomas C.K. Chan, chief scientific officer of ArQule.

"FGFR has been historically difficult to drug with small molecules, and its role in oncology and other diseases suggests that it may be a promising focal point for therapeutic intervention," said Dr. Chan. "The opportunity now exists to expand the number of new chemotypes available for development against disease-relevant kinases in multiple therapeutic areas, since we believe that approximately half of the human kinome may be amenable to this novel mode of inhibition."

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Arqule Inc (ARQL) ARQL. Arqule Inc (ARQL) has Short Term PowerRatings at TradingMarkets. Details on Arqule Inc (ARQL) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.